Novartis, aiming to keep Xolair sales, pushes successor to ph3 by Carly Helfand Thursday, December 6, 2018 With blockbuster Xolair aging, Novartis is looking to usher in a successor to protect its sales. And it got one step closer this week.
Sanofi's Dupixent set for $2.5B in peak asthma sales: analyst by Eric Sagonowsky Monday, October 22, 2018 Sanofi's Dupixent picked up its important asthma approval on Friday, setting the drug up for a multibillion-dollar peak sales boost.
Roche, Novartis to debut new version of aging blockbuster Xolair by Carly Helfand Wednesday, October 3, 2018 Roche and Novartis want to keep aging Xolair competitive for as long as possible, and they recently took a big step forward in doing that.
5 antibody drugs for asthma show benefits but cost too much—ICER by Angus Liu Wednesday, September 26, 2018 Xolair, Nucala, Cinqair, Fasenra and Dupixent will need to take a 50% to 68% discount off the list price to achieve cost-effectiveness, says ICER.
AZ stands up to respiratory rivals with tezepelumab breakthrough by Carly Helfand Friday, September 7, 2018 It hasn’t been an easy summer for AstraZeneca in the respiratory department, but the British drugmaker has finally come up with a win.
Xolair, pressed in asthma, wins food allergy 'breakthrough' by Carly Helfand Monday, August 13, 2018 Roche’s Xolair has seen competitors encroach on its territory over the last few years. But now, it’s ready to carve out a new niche of its own.
5. Xolair by Eric Sagonowsky While a key Xolair patent expires in 2018, it's unclear when any biosimilars could reach the market.
Glaxo aims to lure patients from Novartis' Xolair by Carly Helfand Monday, March 5, 2018 GlaxoSmithKline is taking direct aim at severe asthma challenger Xolair from Novartis.
Biosimilar threat starts to creep up on Roche by Eric Sagonowsky Thursday, October 19, 2017 Roche managed 6% growth in the third quarter, but performance from key cancer meds highlighted biosimilar erosion ahead.
Novartis hopes new diagnostic can help boost Xolair scripts by Carly Helfand Monday, September 26, 2016 New meds are encroaching on a corner of the market for Novartis’ broader severe asthma treatment Xolair. But in response, the company is making it easier to diagnose the patient population it still has on lockdown.
